

# The Medical Letter®

## On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 50 (Issue 1289)  
June 30, 2008

www.medicalletter.org

### IN BRIEF

#### Intensive Glucose Lowering in Type 2 Diabetes

The goal for drug therapy of type 2 diabetes is achieving and maintaining a near-normal glycated hemoglobin (HbA<sub>1C</sub>) concentration without inducing hypoglycemia; the target has generally been an HbA<sub>1C</sub> of 6.5-7.0% or lower. Whether treating to this level prevents macrovascular (cardiovascular) events has been unclear. Now, 2 large randomized, double-blind trials in patients with long-standing diabetes and at high risk for cardiovascular disease have found no decrease in macrovascular events with intensive glucose control.

The ACCORD trial in about 10,000 patients found that patients intensively treated with anti-hyperglycemic drugs, including frequent use of thiazolidinediones, mostly rosiglitazone (*Avandia*), and insulin, with an HbA<sub>1C</sub> target of 6.0% (actual median HbA<sub>1C</sub> 6.4%) did not obtain a significant reduction in major cardiovascular events (the primary endpoint) over a period of 3.5 years. The trial was stopped early because of an unexpected increase in all-cause mortality (257 deaths vs. 203) in intensively treated patients compared to patients with an HbA<sub>1C</sub> target of 7.0-7.9% (actual median HbA<sub>1C</sub> 7.5%). The etiology of the higher mortality is unclear.<sup>1</sup>

The ADVANCE trial in about 11,000 similar patients treated to an HbA<sub>1C</sub> target of 6.5% with a sulfonylurea-based regimen, and infrequent use of thiazolidinediones, also found no decrease in macrovascular events, but no increase in all-cause mortality.<sup>2</sup>

Whether intensive glycemic control would reduce macrovascular events in patients at lower risk has not been established.

1. The ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008; 358:2545.
2. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008; 358:2560.

### The Medical Letter®

On Drugs and Therapeutics

**EDITOR:** Mark Abramowicz, M.D.  
**EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., Weill Medical College of Cornell University  
**DEPUTY EDITOR:** Jean-Marie Pflomm, Pharm.D.  
**ASSISTANT EDITOR, DRUG INFORMATION:** Susan Morey, Pharm.D.  
**CONTRIBUTING EDITOR:** Eric J. Epstein, M.D., Albert Einstein College of Medicine  
**CONTRIBUTING EDITOR, DRUG INTERACTIONS:** Philip D. Hansten, Pharm.D., University of Washington  
**ADVISORY BOARD:**  
Jules Hirsch, M.D., Rockefeller University  
David N. Juurlink, BPhm, M.D., PhD, Sunnybrook Health Sciences Centre  
Richard B. Kim, M.D., University of Western Ontario  
Gerald L. Mandell, M.D., University of Virginia School of Medicine  
Hans Meinertz, M.D., University Hospital, Copenhagen  
Dan M. Roden, M.D., Vanderbilt University School of Medicine  
F. Estelle R. Simons, M.D., University of Manitoba  
Neal H. Steigbigel, M.D., New York University School of Medicine  
**SENIOR ASSOCIATE EDITORS:** Donna Goodstein, Amy Faucard  
**ASSOCIATE EDITOR:** Cynthia Macapagal Covey  
**EDITORIAL FELLOWS:**  
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School  
Lauren K. Schwartz, M.D., Mount Sinai School of Medicine  
**PRODUCTION COORDINATOR:** Cheryl Brown  
**ASSISTANT MANAGING EDITOR:** Liz Donohue  
**MANAGING EDITOR:** Susie Wong

**EXECUTIVE DIRECTOR OF SALES:** Gene Carbona  
**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski  
**DIRECTOR OF MARKETING COMMUNICATIONS:** Joanne F. Valentino  
**VICE PRESIDENT AND PUBLISHER:** Yosef Wissner-Levy  
Founded in 1959 by  
Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations. The content of The Medical Letter is controlled by the Editor, who declares no conflict. The members of the Advisory Board are required to disclose any potential conflict of interest.

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

#### Subscription Services

**Mailing Address:**  
The Medical Letter, Inc.  
1000 Main Street  
New Rochelle, NY 10801-7537  
**Customer Service:**  
Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
Web Site: www.medicalletter.org  
E-mail: custserv@medicalletter.org  
**Permissions:**  
To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

**Subscriptions (US):**  
1 year - \$98; 2 years - \$167;  
3 years - \$235. \$49 per year for students, interns, residents and fellows in the US and Canada.  
CME: \$49 for 26 credits.  
**E-mail site license inquiries to:**  
info@medicalletter.org or call 800-211-2769 x315.  
Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted.

Copyright 2008. ISSN 1523-2859